Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ANKRD10
REST API REST API
Homo sapiens
ANKRD10 is differentially expressed in 261 experiments: 124 organism parts: ovary, uterus, ... (122 more);, 152 disease states: normal, Huntington's disease, ... (150 more);, 90 cell types 430 cell lines 27 compound treatments and 70 other conditions.
Synonyms FLJ20093
Orthologs ankrd10b (Danio rerio)   ankrd10a (Danio rerio)   Ankrd10 (Mus musculus)   A6QNX8_BOVIN (Bos taurus)   ANR10_CHICK (Gallus gallus)   ENSCING00000004245 (Ciona intestinalis)   Ankrd10 (Rattus norvegicus)   ankrd10 (Xenopus laevis)   ANKRD10 (Canis familiaris)   (Compare orthologs)
InterPro Term Ankyrin_rpt, Ankyrin_rpt-contain_dom
Gene Ontology Term protein binding
UniProt Accession Q9H6D6, Q9NXR5, Q9NXQ9, Q8IUW1, B3KTU6
Search EB-eye ENSG00000088448
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-GEOD-22541, ... (24 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (40 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-37, E-MEXP-440, E-MTAB-62
U87
2
E-GEOD-20089, E-MEXP-903
A549
2
E-GEOD-3202, E-GEOD-6013
BT-474
2
E-GEOD-5823, E-GEOD-3529
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
DU145
2
E-GEOD-17482, E-GEOD-20089
424 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-4219, ... (44 experiments)

Factor Value U/D Experiments
human embryonic stem cell
3
E-GEOD-20033, E-GEOD-18265, E-GEOD-18147
CD71+ early erythroid
2
E-AFMX-5, E-TABM-145
CD19+ B cells (neg. sel.)
2
E-AFMX-5, E-TABM-145
mononuclear
2
E-GEOD-13987, E-GEOD-26672
adipocyte
1
E-AFMX-5
activated B-cell
1
E-MEXP-2360
84 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MEXP-1121, E-GEOD-12254, E-GEOD-16363, ... (56 experiments)

Factor Value U/D Experiments
control
3
E-GEOD-21912, E-GEOD-8121, E-GEOD-16363
lung adenocarcinoma
3
E-MTAB-37, E-MTAB-62, E-MEXP-231
glioblastoma
2
E-GEOD-4290, E-MTAB-37
juvenile dermatomyositis
2
E-GEOD-3307, E-MTAB-62
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
Huntington's disease
1
2
E-GEOD-1751, E-AFMX-6, E-GEOD-3790
146 more value(s).


Compound treatment

studied in E-GEOD-5741, E-GEOD-15205, E-TABM-782, E-GEOD-3720, E-GEOD-15811, ... (17 experiments)

Factor Value U/D Experiments
4-hydroxytamoxifen
2
1
E-MEXP-2241
ethanol
1
E-MEXP-2241
TGF
1
E-GEOD-15205
ox-LDL
1
E-GEOD-5741
CNOT7+CNOT8
1
1
E-MEXP-2218
NaOH
1
E-MEXP-2590
21 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519


Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-21374, ... (8 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-20033, E-GEOD-4667, E-MEXP-2283, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-GEOD-22541, E-GEOD-22148, E-GEOD-21138, ... (6 experiments)

Environmental stress
studied in E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, E-MEXP-2340, ... (6 experiments)

Genotype
studied in E-GEOD-22056, E-GEOD-1045, E-GEOD-3494, E-GEOD-17476, E-GEOD-21750, ... (12 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-GEOD-7011, E-GEOD-20504, ... (11 experiments)

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-MEXP-2069, E-GEOD-16363, E-MEXP-935, ... (26 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-6802

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-958, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-1309, E-GEOD-21750, E-MEXP-1403

Population
studied in E-MTAB-197, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-21837, E-GEOD-19445, E-GEOD-19246

Replicate
studied in E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-MEXP-1509, E-GEOD-3697, E-MEXP-1857, E-MEXP-1315 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-7307

Sirna
studied in E-GEOD-21574

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11428

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-33562, E-GEOD-16837, E-GEOD-19246, E-GEOD-19815, E-GEOD-15799, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-3494, E-GEOD-22541, E-GEOD-4922

Processing time: 0.474 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM